Please check your internet connection and try again.
# Clobazam (oral formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties, used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric and adult patients.
## Primary Indications
Adjunctive therapy for seizures in Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initial:** 5 mg twice daily.
* **Titration:** May increase dose by 5-10 mg every week based on clinical response and tolerability.
* **Maintenance:** Doses typically range from 10 mg to 20 mg twice daily.
* **Maximum:** 20 mg twice daily (40 mg daily).
## Pediatric Dosing (LGS)
* **2 years to less than 10 years:**
* **Initial:** 5 mg once daily.
* **Titration:** May increase dose by 2.5-5 mg every week based on clinical response and tolerability.
* **Maintenance:** Doses typically range from 5 mg to 10 mg twice daily.
* **Maximum:** 10 mg twice daily (20 mg daily).
* **10 years and older:**
* **Initial:** 5 mg twice daily.
* **Titration:** May increase dose by 5-10 mg every week based on clinical response and tolerability.
* **Maintenance:** Doses typically range from 10 mg to 20 mg twice daily.
* **Maximum:** 20 mg twice daily (40 mg daily).
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments provided, but consider reduced dosage due to decreased clearance.
* **Renal Impairment:** Use with caution. No specific dose adjustments provided.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, irritability, aggression, fatigue, ataxia, drooling.
* **Serious:** Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), withdrawal symptoms upon abrupt discontinuation, respiratory depression, increased seizure frequency or occurrence of status epilepticus (particularly with abrupt dose changes or in patients with specific seizure types). Clobazam is a Schedule IV controlled substance.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Additive CNS depression. Monitor closely for respiratory depression and sedation.
* **CYP3A4 Inhibitors/Inducers:** Clobazam is metabolized by CYP2C19. Drugs that inhibit or induce CYP2C19 may affect clobazam levels.
* **Antiepileptic Drugs (AEDs):** May alter levels of other AEDs (e.g., valproate, rufinamide). Monitor AED levels and clinical response.
## Monitoring
* Monitor for efficacy (seizure frequency).
* Monitor for adverse effects, especially somnolence, behavioral changes, and signs of severe skin reactions.
* Monitor for signs of withdrawal upon discontinuation.
* Monitor respiratory status, especially when co-administered with other respiratory depressants.
## Clinical Pearls
* Clobazam should be initiated and titrated slowly to minimize adverse effects.
* Avoid abrupt discontinuation; taper dose gradually.
* Dosing for patients with LGS may differ from other indications if clobazam is used off-label. Always confirm indication and dosing.
* Consider CYP2C19 genotype, as this can significantly impact clobazam metabolism and potentially influence efficacy and tolerability.
---
This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines before making any treatment decisions.
